Immunovia AB (OSTO:IMMNOV) Cyclically Adjusted PB Ratio: (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
43 GF Score
Price kr0.18
GF Value kr0.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunovia AB  (OSTO:IMMNOV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Immunovia AB Cyclically Adjusted PB Ratio Related Terms


Immunovia AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Cyclically Adjusted PB Ratio Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.07 0.04

Immunovia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.04 0.03 0.00

OSTO:IMMNOV vs TMO, DHR, IDXX: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, Immunovia AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Cyclically Adjusted PB Ratio falls into.


OSTO:IMMNOV
43GF Score
Immunovia AB OSTO:IMMNOV
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Immunovia AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Immunovia AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.035/134.6100*134.6100
=0.035

Current CPI (Jun. 2026) = 134.6100.

Immunovia AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 101.138 0.000
201612 5.901 102.022 7.786
201703 5.735 102.022 7.567
201706 5.520 102.752 7.231
201709 5.378 103.279 7.009
201712 4.901 103.793 6.356
201803 4.541 103.962 5.880
201806 9.262 104.875 11.888
201809 8.952 105.679 11.403
201812 8.479 105.912 10.777
201903 7.981 105.886 10.146
201906 7.434 106.742 9.375
201909 7.077 107.214 8.885
201912 6.522 107.766 8.147
202003 5.945 106.563 7.510
202006 10.606 107.498 13.281
202009 10.040 107.635 12.556
202012 9.494 108.296 11.801
202103 9.051 108.360 11.244
202106 8.301 108.928 10.258
202109 7.673 110.338 9.361
202112 6.873 112.486 8.225
202203 6.131 114.825 7.187
202206 5.369 118.384 6.105
202209 4.693 122.296 5.166
202212 3.862 126.365 4.114
202303 3.077 127.042 3.260
202306 1.120 129.407 1.165
202309 0.795 130.224 0.822
202312 0.571 131.912 0.583
202403 0.373 132.205 0.380
202406 0.168 132.716 0.170
202409 0.177 132.304 0.180
202412 0.053 132.987 0.054
202503 0.087 132.825 0.088
202506 0.045 133.699 0.045
202509 -0.021 133.480 -0.021
202512 0.096 133.390 0.097
202603 0.069 133.560 0.070
202606 0.035 134.610 0.035

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.18 is trading 203.3% above its estimated GF Value™ of kr0.06. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr0.06 vs. price of kr0.18 (203.3% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for OSTO:IMMNOV

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price
kr0.06
GF Value